期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 15, 期 10, 页码 18333-18348出版社
MDPI
DOI: 10.3390/ijms151018333
关键词
prostate cancer; monocarboxylate transporters; cancer metabolism; therapeutic targets
资金
- Portuguese Foundation for Science and Technology (FCT) [SFRH/BD/61027/2009]
- FCT under the Programa Operacional Tematico Factores de Competitividade (COMPETE) of Quadro Comunitario de Apoio III [PTDC/SAUMET/113415/2009]
- Fundo Comunitario Europeu FEDER
- Fundação para a Ciência e a Tecnologia [SFRH/BD/61027/2009, PTDC/SAU-MET/113415/2009] Funding Source: FCT
Metabolic changes during malignant transformation have been noted for many years in tumours. Otto Warburg first reported that cancer cells preferentially rely on glycolysis for energy production, even in the presence of oxygen, leading to the production of high levels of lactate. The crucial role of lactate efflux and exchange within the tumour microenvironment drew attention to monocarboxylate transporters (MCTs). MCTs have been recognized as promising targets in cancer therapy, and their expression was described in a large variety of tumours; however, studies showing how these isoforms contribute to the acquisition of the malignant phenotype are scarce and still unclear regarding prostate cancer. In this review, we focus on the role for MCTs in cell metabolism, supporting the development and progression of prostate cancer, and discuss the exploitation of the metabolic nature of prostate cancer for therapeutic and diagnostic purposes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据